Active, not recruitingPhase 2NCT01659606
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Studying Dyskeratosis congenita
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Boston Children's Hospital
- Principal Investigator
- Suneet Agarwal, MD, PHD, MD, PhDBoston Children's Hospital
- Intervention
- alemtuzumab(biological)
- Enrollment
- 40 enrolled
- Eligibility
- 65 years · All sexes
- Timeline
- 2012 – 2034
Study locations (13)
- University of Chicago, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Boston Children's Hospital (pediatric patients), Boston, Massachusetts, United States
- Dana-Farber Cancer Institute (adult patients), Boston, Massachusetts, United States
- Children's Mercy Hospital Kansas City, Kansas City, Missouri, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Baylor College of Medicine, Houston, Texas, United States
- Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington, United States
- University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
- Oslo University Hospital, Oslo, Norway
- Karolinska University Hospital, Stockholm, Sweden
Collaborators
Dana-Farber Cancer Institute · Children's Hospital Medical Center, Cincinnati · Fred Hutch/University of Washington/Seattle Children's Cancer Consortium · Baylor College of Medicine · Children's Hospital of Philadelphia · University of Wisconsin, Madison · Karolinska University Hospital · Hackensack Meridian Health · Oslo University Hospital · Children's Mercy Hospital Kansas City · University of Chicago · Massachusetts General Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01659606 on ClinicalTrials.govOther trials for Dyskeratosis congenita
Additional recruiting or active studies for the same condition.